GUIding multi-moDal thErapies against MRD by liquid biopsies - GUIDE.MRD

Project Information

GUIDE.MRD

Grant agreement ID: 101112066

DOI

10.3030/101112066

EC signature date 17 May 2023

Start date 1 May 2023

End date 30 April 2028

Funded under

• Health

Total cost

€ 34 948 425,41

EU contribution

€ 17 660 955,00

Coordinated by

UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF
Germany

CORDIS provides links to public deliverables and publications of HORIZON projects.

Links to deliverables and publications from FP7 projects, as well as links to some specific result types such as dataset and software, are dynamically retrieved from OpenAIRE .

Deliverables

Documents, reports (4)

Updated Data Management Plan (DMP)

The DMP will be updated based on the progress of WP2 and WP3 and associated deliverables

Healthcare pathway map

Visualization of existing and the (ideal) pathway according to a common framework

Stakeholder/system map

A map representing connectivity, fragmentation and factors in the system that may influence adoption of new technologies and solutions.

Dissemination and exploitation plan, including IPR protection management, communication activities

An initial dissemination, communication and exploitation plan will be created when the project begins and updated yearly. The plan will be organized according to the specific conditions on Availability, Accessibility and Affordability (‘3A’).

Websites, patent fillings, videos etc. (1)

Development of project website and project visual identity

The GUIDE.MRD website will be accessible on the internet with internal access that is password protected

Publications

Conference proceedings (1)

Creation of the ideal health care pathway for integrating ctDNA testing into clinical practice through multi-stakeholder engagement.

Author(s): Lidewij Vat, Brian Goodman, Eleonora Barile, Estevan Kiernan, Bianca Cucoş, Ana Martins, Mohan Bolisetty, Cathy Elks, Ryan Demers, Muriel De Vos, Riccardo Bertini, Trixia Camacho, Daniel J. Smit, Lui
Published in: Journal of Clinical Oncology, Issue 43, 2025, ISSN 0732-183X
Publisher: American Society of Clinical Oncology (ASCO)
DOI: 10.1200/JCO.2025.43.16_SUPPL.E23032

Peer reviewed articles (2)

Outlining the statistical analysis of longitudinal ctDNA assays to determine minimal residual disease in patients with pancreatic ductal adenocarcinoma: the GUIDE.MRD project

Author(s): Brune De Dreuille, Evangelina López De Maturana, Claus Lindbjerg Andersen, Ed Schuuring, Ellen Heitzer, Lidewij Vat, Mark Rogers, Riccardo Bertini, Estevan Kiernan, Ephrem Chin, J. Carl Barrett, Josh
Published in: Pancreatology, Issue 24, 2024, ISSN 1424-3903
Publisher: Elsevier BV
DOI: 10.1016/J.PAN.2024.05.293

237TiP GUIDE.MRD: A Consortium guiding multi-modal therapies against minimal residual disease (MRD) by liquid biopsy to assess implementation of circulating tumor DNA (ctDNA) in clinical practice to i

Author(s): K. Pantel, C. Lindbjerg Andersen, E. Schuuring, N. Malats, E. Heitzer, L. Vat, E. Kiernan, E. Chin, J.C. Barrett, J.R. Kapp, M. Thomas, M. Gerling, M. Reck, M. Löhr, P. Hofman, J.T.J.N. Hiltermann, C
Published in: Annals of Oncology, Issue 34, 2025, ISSN 0923-7534
Publisher: Elsevier BV
DOI: 10.1016/J.ANNONC.2023.09.2960EXTERNALLINK